Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trialAlbert M. Maguire, Jean Bennett, Daniel C. Chung et al.|The Lancet|2009Cited by 857
Gene Therapy for Leber's Congenital Amaurosis is Safe and Effective Through 1.5 Years After Vector AdministrationFrancesca Simonelli, Alberto Auricchio, Albert M. Maguire et al.|Molecular Therapy|2009Cited by 551
AAV2 Gene Therapy Readministration in Three Adults with Congenital BlindnessJean Bennett, Albert M. Maguire, Manzar Ashtari et al.|Science Translational Medicine|2012Cited by 390
Gene mutation spectrum and genotype-phenotype correlation in a cohort of Chinese osteogenesis imperfecta patients revealed by targeted next generation sequencingY. Liu, Ke Li, Asan et al.|Osteoporosis International|2017Cited by 77
Correction to: Gene mutation spectrum and genotype-phenotype correlation in a cohort of Chinese osteogenesis imperfecta patients revealed by targeted next generation sequencingY. Liu, Mingyang Li, Asan et al.|Osteoporosis International|2017Cited by 49